Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10. [electronic resource]
Producer: 20141030Description: 691-8 p. digitalISSN:- 1534-4681
- Animals
- Apoptosis
- Cell Proliferation
- Combined Modality Therapy
- Disease Models, Animal
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Humans
- Immunoenzyme Techniques
- Male
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Neovascularization, Pathologic -- prevention & control
- Oncolytic Virotherapy
- Pancreatic Neoplasms -- genetics
- Protein Kinase Inhibitors -- therapeutic use
- Quinazolines -- therapeutic use
- Simplexvirus -- physiology
- Survival Rate
- Tumor Cells, Cultured
- Virus Internalization
- Virus Replication
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.